Abstract
Risperidone, an atypical antipsychotic medication, is recommended as a first line treatment for acute mania in patients with bipolar disorder I (BD I). It is unknown if continuing treatment with risperidone adjunct to lithium or valproate after remission of the manic episode offers additional benefit in prevention of mood episode relapse. A post-hoc subgroup analysis was conducted using data from a 52-week, double-blind, placebo controlled trial involving 93 patients treated with oral risperidone adjunct to mood stabilizer, randomized to arms discontinuing risperidone at entry ("0-week arm"), 24 weeks after entry ("24-week arm") or continuing risperidone ("52-week arm"). Time to any episode, manic episode, and depressive episode was compared between arms using Cox regression models. Time to any mood episode was longer in the 24-week arm versus the 0-week arm (HR: 0.57, 95% CI: 0.31-1.05, P = 0.07) and shorter in the 52-week arm versus 24-week arm (HR: 1.85, 95% CI: 1.00-3.41, P = 0.05), though these results were not significant. Time to relapse into manic episode was significantly longer in the 24-week arm versus 0-week arm (HR: 0.14, 95% CI: 0.03, 0.65, P = 0.01). No other significant differences were observed between arms. Th...Continue Reading
References
Apr 1, 1979·The British Journal of Psychiatry : the Journal of Mental Science·S A Montgomery, M Asberg
Nov 1, 1978·The British Journal of Psychiatry : the Journal of Mental Science·R C YoungD A Meyer
Jan 1, 1987·Acta Psychiatrica Scandinavica. Supplementum·O LingjaerdeK Elgen
Mar 3, 1998·Psychiatry Research·M K SpearingW Nolen
Jul 2, 2002·The American Journal of Psychiatry·Gary S SachsCharles L Bowden
Dec 31, 2002·The American Journal of Psychiatry·Andrea FagioliniEllen Frank
Feb 4, 2003·The British Journal of Psychiatry : the Journal of Mental Science·Laksami N YathamArun Ravindran
Feb 1, 1960·Journal of Neurology, Neurosurgery, and Psychiatry·M HAMILTON
Jun 1, 2004·The American Journal of Psychiatry·Robert M A HirschfeldFred Grossman
Dec 2, 2004·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Anatoly B SmulevichFred Grossman
Jun 14, 2005·Schizophrenia Research·Guy Chouinard, Howard C Margolese
Sep 2, 2005·The British Journal of Psychiatry : the Journal of Mental Science·Sumant KhannaMichelle Kramer
Jul 20, 2006·The Journal of Clinical Psychiatry·Jennifer E WildesAndrea Fagiolini
Nov 20, 2009·Bipolar Disorders·Wayne MacfaddenRamy Mahmoud
Mar 17, 2010·Biological Psychiatry·Jorge A QuirozVivek Kusumakar
May 21, 2010·Drugs·Emma D Deeks
Oct 20, 2011·Nature Reviews. Endocrinology·Marc De HertChristoph U Correll
Apr 17, 2012·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Eduard VietaAndreas Schreiner
Dec 15, 2012·International Clinical Psychopharmacology·Vivek SinghJim Mintz
Jun 26, 2013·Nordic Journal of Psychiatry·Ludovic SamalinPierre-Michel Llorca
Oct 16, 2015·Molecular Psychiatry·L N YathamH Wong
Mar 15, 2018·Bipolar Disorders·Lakshmi N YathamMichael Berk
Citations
May 28, 2020·International Clinical Psychopharmacology·Yoo Hyun UmJong-Hyun Jeong
Feb 23, 2021·Expert Opinion on Pharmacotherapy·Ahmad Sleem, Rif S El-Mallakh
May 9, 2021·Current Psychiatry Reports·Kamyar KeramatianLakshmi N Yatham